Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Common Stock Options Outstanding and Related Activity

The following is a summary of stock option information and weighted average exercise prices:

	2022			2021
	Number of Options	Weighted Average Exercise Price		Number of Options	Weighted Average Exercise Price
Outstanding at January 1	10,357,495	$	1.87	10,215,834	$	0.45
Granted	79,909	1.83		2,623,689	6.30
Exercised	(816,866)	0.32		(704,672)	0.63
Canceled	(1,108,020)	3.70		(1,769,796)	0.75
Expired	(129,433)	4.34		(7,560)	0.12
Outstanding at December 31	8,383,085	1.74		10,357,495	1.87
Exercisable at December 31	7,356,920	$	1.45	6,712,145	$	0.73

Schedule of Key Weighted Average Assumptions for 2021 Grants

The key assumptions for grants presented on a weighted average basis are as follows:

	Year Ended December 31,
	2022		2021
Expected volatility	68.2	%	64.9	%
Risk-free rate	2.0	%	0.9	%
Expected term in years	6.1		5.9
Dividend yield	—	%	—	%

Summary of RSU information

The following is a summary of RSU information and weighted average grant date fair values for the Company's RSUs:

	Year Ended December 31,
	2022				2021
	Shares		Weighted Average Grant Date Fair Value		Shares	Weighted Average Grant Date Fair Value
Unvested at January 1	$	4,070,267	$	4.08	—	$	—
Granted	7,641,313		2.45		4,085,666	4.08
Vested	(1,369,236)		3.83		—	—
Forfeited	(3,460,494)		3.32		(15,399)	4.67
Unvested at December 31	$	6,881,850	$	2.70	4,070,267	$	4.08

Performance Restricted Stock Units

During the year ended December 31, 2022, the Company granted 1,854,105 performance restricted stock units ("PRSU"), of which 631,579 were forfeited. Stock-based compensation related to PRSU grants was $428 for the year ended December 31, 2022. The PRSU awards function in the same manner as restricted stock units except that vesting terms are based on achievement of performance measures, such as the achievement of net revenue targets

and obtaining certain FDA regulatory results. PRSUs are recognized as expense following a graded vesting schedule with their performance re-assessed and updated on a quarterly basis, or more frequently as changes in facts and circumstances warrant. The aggregated fair value of PRSUs granted during the year ended December 31, 2022 was $4,817. The weighted average grant date fair value of PRSUs granted during the year ended December 31, 2022 was $2.60 per unit.

Schedule of Stock-based Compensation Expense

Total stock-based compensation was recognized as follows (in thousands):

	Year Ended December 31,
	2022		2021
General and administrative	$	7,117	$	1826
Sales and marketing	2,216		939
Research and development	3,523		1,494
Total stock-based compensation	$	12,856	$	4,259